Notably, lenvatinib was found to downregulate PKC levels and suppress the PKCa/ZFP64/CSF1 pathway, thus overcoming resistance to anti-PD-1 treatment in HCC, unlike sorafenib. The gene discussed is PRRT2; the disease is hepatocellular carcinoma.